Chris is a member of Valo’s Board of Directors and is a Growth Partner at Flagship Pioneering. He joined Flagship in 2023 with more than thirty years of public and private pharmaceutical and biotechnology industry experience. Most recently, he was President and Chief Executive Officer of Aprea Therapeutics where he served as a member of the board since 2016, including as Chairman from 2020-2023. Chris has also served in executive leadership positions at several emerging biotech companies including: Chief Executive Officer of Novira, a privately held antiviral drug discovery company until it was acquired by Johnson & Johnson; Chief Financial Officer of Omthera Pharmaceuticals, Inc., a Nasdaq-listed specialty pharmaceuticals company focused on new therapies for dyslipidemia until it was acquired by AstraZeneca Plc; and Senior Vice President of Administration and Chief Financial Officer at Medarex, Inc, a biopharmaceutical company focused on antibody-based therapeutic products for oncology, inflammation, autoimmune disorders, and infectious diseases until it was acquired by Bristol-Myers Squibb. Before joining Medarex, Chris held various corporate finance and capital markets positions, including Managing Director at Merrill Lynch, in New York and London for both Merrill Lynch and JP Morgan Chase & Co for nearly twenty years.
Chris currently serves on the board of directors of Integra LifeSciences Inc., where he chairs the Audit and Finance Committees, Alltrna Therapeutics, Ring Therapeutics, and Omega Therapeutics, where he chairs the board. He received an M.B.A. from the Wharton School at the University of Pennsylvania and an A.B. from Princeton University.